OBIGEN PHARMA INC. Announces U.S. FDA Acceptance of Phase II IND for OBI-858 in Aesthetic Glabellar Lines

OBIGEN PHARMA INC. Launches Phase III Clinical Trial of World’s First 760 kDa Long-Acting Botulinum Toxin OBI-858 in Taiwan

OBIGEN Announces Taiwan Emerging Board Listing to Accelerate Global Botulinum Toxin Expansion

OBIGEN Pharma’s Phase II Clinical Trial Results for Novel 760 kDa Botulinum Toxin Published in International Journal Dermatology and Therapy

OBIGEN’s Self-Developed Taiwanese Novel Botulinum Toxin for Aesthetics Succeeds in Phase 2 Trial

OBIGEN PHARMA has achieved the objectives of interim analysis for Phase 2 clinical trial of OBI-858

OBIGEN Pharma Appoints New CEO to Lead IPO Growth

OBIGEN and A Phase I Clinical Trial Physician Present New 760 kDa Taiwan Botulinum Toxin at AMWC Japan 2024

OBI-858 Approved by INTELLECTUAL PROPERTY CORPORATION OF MALAYSIA (MyIPO), No. MY-205101-A

OBI-858 Approved by TAIPEI GRAND MOSQUE FOUNDATION For Halal Certificate No. TGM.N13-240702-250831-01B55-1